Inocras Inc. (San Diego, CA; President & CEO: Jehee Suh) and Summit Pharmaceuticals International Corporation (Tokyo, Japan; President & CEO: Katsuya Okuyama) have signed a Memorandum of Understanding (MOU) to explore the commercialization of their whole genome sequencing (WGS) analysis services. This partnership aims to transform healthcare in Japan by utilizing genomic data and bioinformatics to enhance the understanding and treatment of cancer and other genetic disorders.
Whole genome sequencing generates comprehensive data by mapping an individual’s entire genome. Inocras’ advanced bioinformatics platform then processes this data into actionable clinical insights, supporting precise diagnoses and enabling personalized treatments. As a leader in WGS and bioinformatics, Inocras has partnered with SPI to introduce these cutting-edge genomic solutions to the Japanese market.
One of the key features of Inocras’ proprietary technology is its ability to perform WGS on formalin-fixed paraffin-embedded (FFPE) samples, which are commonly used in clinical settings. This technology, combined with Inocras’ robust bioinformatics pipeline, is poised to offer valuable insights into genomic medicine.
The two companies will now work together to develop a strategic business plan for integrating WGS into Japan’s healthcare system. This includes assessing market potential, designing operational models, and evaluating the clinical impact of genomic medicine. The collaboration will also gather input from key opinion leaders and other stakeholders to ensure its success. Future plans include establishing a WGS laboratory and enhancing local bioinformatics capabilities.
“Inocras is thrilled to bring our advanced WGS and bioinformatics expertise to Japan, offering solutions that no other provider currently delivers here,” said Jehee Suh, CEO of Inocras. “Working alongside SPI, we are creating a pathway to revolutionize patient care through data-driven innovation.”
“Japan is at a critical juncture in embracing genomic medicine, and this partnership with Inocras is perfectly timed to accelerate that transformation,” said Katsuya Okuyama, CEO of SPI.
About Inocras Inc.:
Inocras is an AI-driven company focused on providing critical insights for cancer and rare disease patients through whole genome sequencing. The company offers its proprietary testing products, CancerVision and RareVision, and provides research services for pharmaceutical and biotechnology companies as well as academic research institutions. Inocras’ services are conducted through its CAP/CLIA-certified laboratory, utilizing a unique, IP-protected bioinformatics pipeline. The company is committed to unlocking the full potential of genomic data to enable precision health for all.
About Summit Pharmaceuticals International Corporation (SPI):
SPI offers a broad range of high-quality products and services to the pharmaceutical industry, from research equipment and biological resources for drug discovery to pharmaceutical licensing, research partnerships, and the production of active pharmaceutical ingredients (APIs) and generics. SPI is a subsidiary of Sumitomo Corporation, a global leader with a network of 127 locations in 65 countries and 20 locations within Japan (as of April 1, 2024).
